Clara Hwang

Clara Hwang

Auto-generated profile, based on publicly available information

Clara Hwang

Department of Internal Medicine, Division of Hematology and Oncology Henry Ford Health Detroit Michigan USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1996 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
VBVivek Bajaj
Vivek Bajaj
RLRobin L. Lucas
Robin L. Lucas
CHClara Hwang
Clara Hwang
CLCatherine A. Lee
Catherine A. Lee

1 November 1995 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
VBVivek Bajaj
Vivek Bajaj
CHClara Hwang
Clara Hwang
CLCatherine A. Lee
Catherine A. Lee

19 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DKDejuan Kong
Dejuan Kong
EHElisabeth Heath
Elisabeth Heath
WCWei Chen
Wei Chen
MCMichael L. Cher
Michael L. Cher
IPIsaac Powell
Isaac Powell
FSFazlul Sarkar
Fazlul Sarkar
The emergence of castrate-resistant prostate cancer (CRPC) contributes to the high mortality of patients diagnosed with prostate cancer (PCa), which in part could be attributed to the existence and the emergence of cancer stem cells (CSCs). Recent studies have shown that deregulated expression of microRNAs (miRNAs) contributes to the initiation and progression of PCa. Among several known miRNAs, let-7 family appears to play a key role in the recurrence and progression of PCa by regulating CSCs; however, the mechanism by which let-7 family contributes to PCa aggressiveness is unclear. Enhancer of Zeste homolog 2 (EZH2), a putative target of let-7 family, was demonstrated to control stem cell function. In this study, we found loss of let-7 family with corresponding over-expression of EZH2 in human PCa tissue specimens, especially in higher Gleason grade tumors. Overexpression of let-7 by transfection of let-7 precursors decreased EZH2 expression and repressed clonogenic ability and sphere-forming capacity of PCa cells, which was consistent with inhibition of EZH2 3′UTR luciferase activity. We also found that the treatment of PCa cells with BR-DIM (formulated DIM: 3,3′-diindolylmethane by Bio Response, Boulder, CO, abbreviated as BR-DIM) up-regulated let-7 and down-regulated EZH2 expression, consistent with inhibition of self-renewal and clonogenic capacity. Moreover, BR-DIM intervention in our on-going phase II clinical trial in patients prior to radical prostatectomy showed upregulation of let-7 consistent with down-regulation of EZH2 expression in PCa tissue specimens after BR-DIM intervention. These results suggest that the loss of let-7 mediated increased expression of EZH2 contributes to PCa aggressiveness, which could be attenuated by BR-DIM treatment, and thus BR-DIM is likely to have clinical impact.

1 February 1999 in Urology
Verified
Journal Article
Closed access
MSMartin G. Sanda
Martin G. Sanda
DSDavid C. Smith
David C. Smith
LCLinda G. Charles
Linda G. Charles
CHClara Hwang
Clara Hwang
KPKenneth J. Pienta
Kenneth J. Pienta
JMJames E. Montie
James E. Montie

22 June 2012 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
CHClara Hwang
Clara Hwang
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy associated with a survival benefit in castrate-resistant prostate cancer. Toxicity is typical of other cytotoxic agents, with myelosuppression being the dose-limiting toxicity and neurotoxicity also a notable side effect for some patients. Unfortunately, a significant proportion of men with castrate-resistant prostate cancer will not respond to docetaxel-based therapy and all patients will ultimately develop resistance. Because it is an effective therapy, docetaxel is likely to remain an important part of the treatment arsenal against metastatic prostate cancer for the foreseeable future, despite its toxicities and limitations. Overcoming docetaxel resistance has been a challenge since docetaxel was first established as front-line therapy for metastatic castrate-resistant prostate cancer. Recent studies have shown that several new drugs, including cabazitaxel and abiraterone, are effective after docetaxel failure, dramatically changing the therapeutic landscape for these patients. In addition, a greater understanding of the mechanisms underlying docetaxel resistance has led to several new treatment approaches which hold promise for the future. This review will discuss recent therapeutic advances in metastatic castrate-resistant prostate cancer as well as ongoing clinical trials.

2 August 2010 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
CHClara Hwang
Clara Hwang
EHElisabeth Heath
Elisabeth Heath
Prostate cancer remains a significant public health problem, with limited therapeutic options in the setting of castrate-resistant metastatic disease. Angiogenesis inhibition is a relatively novel antineoplastic approach, which targets the reliance of tumor growth on the formation of new blood vessels. This strategy has been used successfully in other solid tumor types, with the FDA approval of anti-angiogenic agents in breast, lung, colon, brain, and kidney cancer. The application of anti-angiogenic therapy to prostate cancer is reviewed in this article, with attention to efficacy and toxicity results from several classes of anti-angiogenic agents. Ultimately, the fate of anti-angiogenic agents in prostate cancer rests on the eagerly anticipated results of several key phase III studies.